CD45

Ongoing clinical trials and approved products targeting CD45, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

Target note

Full name

CD45 (leukocyte common antigen, PTPRC gene)

Nature

Membrane tyrosine phosphatase present on all nucleated hematopoietic cells.

Normal expression

Leukocytes of the bone marrow, spleen, lymph nodes and blood.

Disease expression

Acute leukemias, myelodysplastic syndromes, lymphomas.

Value

Irradiating the bone marrow and leukemic sites before stem cell transplant, to intensify conditioning without increasing non-hematologic toxicity.

Approaches

Anti-CD45 antibodies: ¹³¹I-apamistamab (Iomab-B), ²¹¹At-BC8-B10, ⁹⁰Y-BC8.

Indications explored

Conditioning for allogeneic transplant (refractory acute myeloid leukemia, phase 3 SIERRA), before CAR-T, non-malignant diseases.

Points of caution

Aplasia expected (transplant is mandatory); liver toxicity (veno-occlusive disease) is limiting with ²¹¹At.

Ongoing therapy trials · 8Open in the radar →

Cite this page

CD45. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/cd45/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.